This technology was first reported in the context of NIPD for several autosomal recessive conditions, including cystic fibrosis (CFTR), β-thalassaemia (HBB), and congenital adrenal hyperplasia (CYP21A2)[113]. The gene discussed is HBB; the disease is cystic fibrosis.